This study tested whether the addition of anti-MAP antimicrobial therapy (RHB-104) to standard-of-care therapy, including immunosuppressive therapy with TNF inhibitors, was superior to placebo plus standard-of-care for the therapy of patients with moderately to severely active Crohn’s disease. Here, TNF is linked to Crohn disease.